Superiority of Immunotherapy to Benzodiazepines and No Treatment in Down Syndrome Regression Disorder (P8-6.007)
This study sought to assess the efficacy of lorazepam, IVIg and no treatment in individuals with Down Syndrome Regression Disorder (DSRD).
Authors
- Eileen A. Quinn
- Robyn A. Filipink
- Natalie K. Boyd
- Panteha Hayati Rezvan (ORCID: https://orcid.org/0000-0001-6360-8388)
- Michael S. Rafii (ORCID: https://orcid.org/0000-0003-2640-2094)
- Saba Jafarpour (ORCID: https://orcid.org/0000-0001-8029-785X)
- Jonathan Douglas Santoro (ORCID: https://orcid.org/0000-0002-8350-8234)
- Kristen S. Fisher (ORCID: https://orcid.org/0000-0002-1598-8571)
- Catherine Franklin (ORCID: https://orcid.org/0000-0002-9011-1606)
- Nidhiben Anadani
- Mellad Khoshnood (ORCID: https://orcid.org/0000-0003-2232-8341)
- Noemi Alice Spinazzi (ORCID: https://orcid.org/0000-0001-5009-7670)
- Benjamin Vogel
- Lina Nguyen
- Lilia Kazerooni (ORCID: https://orcid.org/0009-0003-4147-5395)
- Melanie Manning
Institutions
- Children's Hospital of Los Angeles (US)
- University of California, San Francisco (US)
- Baylor College of Medicine (US)
- Mater Research (AU)
- Children's Hospital of Pittsburgh (US)
- Stanford Medicine (US)
- University of Oklahoma Health Sciences Center (US)
- University of Toledo (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208699
- Primary Topic
- Genetics and Neurodevelopmental Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00